Substance use outcomes from the Child/Adolescent Anxiety Multimodal Extended Long-term Study (CAMELS) / Thomas M. OLINO ; Anne Marie ALBANO ; Courtney P. KEETON ; Dara SAKOLSKY ; Boris BIRMAHER ; John PIACENTINI ; Tara S. PERIS ; Scott N. COMPTON ; Elizabeth GOSCH ; Golda S. GINSBURG ; Elizabeth L. PINNEY ; Philip C. KENDALL in Journal of Child Psychology and Psychiatry, 65-7 (July 2024)  

Public ISBD [article]  inJournal of Child Psychology and Psychiatry > 65-7 (July 2024) . - p.910-920 Titre : Substance use outcomes from the Child/Adolescent Anxiety Multimodal Extended Long-term Study (CAMELS) Type de document : Texte imprimé et/ou numérique Auteurs : Thomas M. OLINO, Auteur ; Anne Marie ALBANO, Auteur ; Courtney P. KEETON, Auteur ; Dara SAKOLSKY, Auteur ; Boris BIRMAHER, Auteur ; John PIACENTINI, Auteur ; Tara S. PERIS, Auteur ; Scott N. COMPTON, Auteur ; Elizabeth GOSCH, Auteur ; Golda S. GINSBURG, Auteur ; Elizabeth L. PINNEY, Auteur ; Philip C. KENDALL, Auteur Article en page(s) : p.910-920 Langues : Anglais (eng) Index. décimale : PER Périodiques Résumé : Background Substance use problems and anxiety disorders are both highly prevalent and frequently cooccur in youth. The present study examined the benefits of successful anxiety treatment at 3-12?years after treatment completion on substance use outcomes (i.e. diagnoses and lifetime expected use). Methods The sample was from the Child/Adolescent Anxiety Multimodal Extended Long-term Study (CAMELS), a naturalistic follow-up study to the Child/Adolescent Anxiety Multimodal Study (CAMS) which randomized youth to cognitive behavioral therapy (CBT; Coping cat), medication (sertraline), their combination, or pill placebo. The first CAMELS visit occurred an average of 6.5?years following CAMS randomization. Participants were 319 youth (65.4% of the CAMS sample), aged 7-17?years at CAMS baseline assessment with a mean age of 17.6?years (range: 11-26?years) at the time of the first CAMELS follow-up. Substance use outcomes included diagnoses as well as lifetime substance use (i.e. alcohol and tobacco use). Results Eleven of 319 (3.4%) CAMELS participants were diagnosed with a substance use disorder at the initial follow-up visit. When compared to the population lifetime rate of 11.4%, the rate of diagnoses in the posttreated sample was significantly lower. Additionally, rates of lifetime alcohol use were lower than population rates at the initial and final follow-up visits. Rates of lifetime tobacco use were similarly lower than lifetime population rates at the initial visit (driven by significantly lower rates in the CBT treatment condition), but higher by the final visit. Furthermore, treatment remission (but not treatment response) was associated with a lower rate of substance use diagnoses at the initial follow-up visit, although rates of lifetime alcohol and tobacco use did not differ by treatment outcome. Conclusions Anxiety treatments confer a beneficial impact on problematic substance use (i.e. diagnoses) as well as on expected substance use (i.e. alcohol and tobacco use) for on average, a period of 6.5?years. En ligne : https://doi.org/10.1111/jcpp.13926 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=532 [article] Substance use outcomes from the Child/Adolescent Anxiety Multimodal Extended Long-term Study (CAMELS) [Texte imprimé et/ou numérique] / Thomas M. OLINO, Auteur ; Anne Marie ALBANO, Auteur ; Courtney P. KEETON, Auteur ; Dara SAKOLSKY, Auteur ; Boris BIRMAHER, Auteur ; John PIACENTINI, Auteur ; Tara S. PERIS, Auteur ; Scott N. COMPTON, Auteur ; Elizabeth GOSCH, Auteur ; Golda S. GINSBURG, Auteur ; Elizabeth L. PINNEY, Auteur ; Philip C. KENDALL, Auteur . - p.910-920. Langues : Anglais (eng) in Journal of Child Psychology and Psychiatry > 65-7 (July 2024) . - p.910-920 Index. décimale : PER Périodiques Résumé : Background Substance use problems and anxiety disorders are both highly prevalent and frequently cooccur in youth. The present study examined the benefits of successful anxiety treatment at 3-12?years after treatment completion on substance use outcomes (i.e. diagnoses and lifetime expected use). Methods The sample was from the Child/Adolescent Anxiety Multimodal Extended Long-term Study (CAMELS), a naturalistic follow-up study to the Child/Adolescent Anxiety Multimodal Study (CAMS) which randomized youth to cognitive behavioral therapy (CBT; Coping cat), medication (sertraline), their combination, or pill placebo. The first CAMELS visit occurred an average of 6.5?years following CAMS randomization. Participants were 319 youth (65.4% of the CAMS sample), aged 7-17?years at CAMS baseline assessment with a mean age of 17.6?years (range: 11-26?years) at the time of the first CAMELS follow-up. Substance use outcomes included diagnoses as well as lifetime substance use (i.e. alcohol and tobacco use). Results Eleven of 319 (3.4%) CAMELS participants were diagnosed with a substance use disorder at the initial follow-up visit. When compared to the population lifetime rate of 11.4%, the rate of diagnoses in the posttreated sample was significantly lower. Additionally, rates of lifetime alcohol use were lower than population rates at the initial and final follow-up visits. Rates of lifetime tobacco use were similarly lower than lifetime population rates at the initial visit (driven by significantly lower rates in the CBT treatment condition), but higher by the final visit. Furthermore, treatment remission (but not treatment response) was associated with a lower rate of substance use diagnoses at the initial follow-up visit, although rates of lifetime alcohol and tobacco use did not differ by treatment outcome. Conclusions Anxiety treatments confer a beneficial impact on problematic substance use (i.e. diagnoses) as well as on expected substance use (i.e. alcohol and tobacco use) for on average, a period of 6.5?years. En ligne : https://doi.org/10.1111/jcpp.13926 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=532

Symptom-specific effects of cognitive-behavioral therapy, sertraline, and their combination in a large randomized controlled trial of pediatric anxiety disorders / Matti CERVIN in Journal of Child Psychology and Psychiatry, 61-4 (April 2020)  

Public ISBD [article]  inJournal of Child Psychology and Psychiatry > 61-4 (April 2020) . - p.492-502 Titre : Symptom-specific effects of cognitive-behavioral therapy, sertraline, and their combination in a large randomized controlled trial of pediatric anxiety disorders Type de document : Texte imprimé et/ou numérique Auteurs : Matti CERVIN, Auteur ; Eric A. STORCH, Auteur ; John PIACENTINI, Auteur ; Boris BIRMAHER, Auteur ; Scott N. COMPTON, Auteur ; Anne Marie ALBANO, Auteur ; Elizabeth GOSCH, Auteur ; John T. WALKUP, Auteur ; Philip C. KENDALL, Auteur Article en page(s) : p.492-502 Langues : Anglais (eng) Mots-clés : CBT/cognitive behavior therapy  anxiety/anxiety disorders  child/adolescent  clinical trials  pharmacotherapy Index. décimale : PER Périodiques Résumé : BACKGROUND: Pediatric anxiety disorders are highly prevalent and associated with significant functional disabilities and lifelong morbidity. Cognitive-behavioral therapy (CBT), sertraline, and their combination are effective treatments, but little is known about how these treatments exert their effects. METHODS: Using network intervention analysis (NIA), we analyzed data from the largest randomized controlled treatment trial of pediatric anxiety disorders (Child/Adolescent Anxiety Multimodal Study, NCT00052078, clinicaltrials.gov/ct2/show/NCT00052078) and outlined the causal symptom domain-specific effects of CBT, sertraline, and their combination over the course of the 12-week treatment while taking into account both specificity and overlap between symptom domains. RESULTS: All active treatments produced positive effects with the most pronounced and consistent effects emerging in relation to psychological distress, family interference, and avoidance. Psychological distress was consistently the most and physical symptoms the least central symptom domain in the disorder network. CONCLUSIONS: All active treatments showed beneficial effects when compared to placebo, and NIA identified that these effects were exerted similarly across treatments and primarily through a reduction of psychological distress, family interference, and avoidance. CBT and sertraline may have differential mechanisms of action in relation to psychological distress. Given the lack of causal effects on interference outside family and physical symptoms, interventions tailored to target these domains may aid in the building of more effective treatments. Psychological distress and avoidance should remain key treatment focuses because of their central roles in the disorder network. The findings inform and promote developing more effective interventions. En ligne : http://dx.doi.org/10.1111/jcpp.13124 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=421 [article] Symptom-specific effects of cognitive-behavioral therapy, sertraline, and their combination in a large randomized controlled trial of pediatric anxiety disorders [Texte imprimé et/ou numérique] / Matti CERVIN, Auteur ; Eric A. STORCH, Auteur ; John PIACENTINI, Auteur ; Boris BIRMAHER, Auteur ; Scott N. COMPTON, Auteur ; Anne Marie ALBANO, Auteur ; Elizabeth GOSCH, Auteur ; John T. WALKUP, Auteur ; Philip C. KENDALL, Auteur . - p.492-502. Langues : Anglais (eng) in Journal of Child Psychology and Psychiatry > 61-4 (April 2020) . - p.492-502 Mots-clés : CBT/cognitive behavior therapy  anxiety/anxiety disorders  child/adolescent  clinical trials  pharmacotherapy Index. décimale : PER Périodiques Résumé : BACKGROUND: Pediatric anxiety disorders are highly prevalent and associated with significant functional disabilities and lifelong morbidity. Cognitive-behavioral therapy (CBT), sertraline, and their combination are effective treatments, but little is known about how these treatments exert their effects. METHODS: Using network intervention analysis (NIA), we analyzed data from the largest randomized controlled treatment trial of pediatric anxiety disorders (Child/Adolescent Anxiety Multimodal Study, NCT00052078, clinicaltrials.gov/ct2/show/NCT00052078) and outlined the causal symptom domain-specific effects of CBT, sertraline, and their combination over the course of the 12-week treatment while taking into account both specificity and overlap between symptom domains. RESULTS: All active treatments produced positive effects with the most pronounced and consistent effects emerging in relation to psychological distress, family interference, and avoidance. Psychological distress was consistently the most and physical symptoms the least central symptom domain in the disorder network. CONCLUSIONS: All active treatments showed beneficial effects when compared to placebo, and NIA identified that these effects were exerted similarly across treatments and primarily through a reduction of psychological distress, family interference, and avoidance. CBT and sertraline may have differential mechanisms of action in relation to psychological distress. Given the lack of causal effects on interference outside family and physical symptoms, interventions tailored to target these domains may aid in the building of more effective treatments. Psychological distress and avoidance should remain key treatment focuses because of their central roles in the disorder network. The findings inform and promote developing more effective interventions. En ligne : http://dx.doi.org/10.1111/jcpp.13124 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=421

---

1 (1 - 2 / 2)